Marimed earnings release, May 13, 2026

Marimed Inc. (MRMD) · Form 8-K, Item 2.02 · Filed · SEC filing

MariMed Reports First Quarter 2026 Earnings

NORWOOD, MA, May 13, 2026

- MariMed Inc. (“MariMed” or the “Company”) (CSE: MRMD) (OTCQB: MRMD), a leading multi-state cannabis operator focused on improving lives every day, today announced its financial results for the first quarter ended March 31, 2026.

Financial Highlights¹

The following table summarizes the Company's consolidated financial highlights (in millions, except percentage amounts):¹

See the reconciliations of non-GAAP financial measures to the most directly comparable GAAP measures and additional information about non-GAAP measures in the section entitled “Discussion of Non-GAAP Financial Measures” below and in the financials information included herewith.

Management Commentary

"The first quarter reflected MariMed's continued year-over-year growth, supported by expanded wholesale distribution, retail growth, and continued execution of our 'Expand the Brand' strategy of making our top-selling brands accessible to more people in both existing and new markets," said Jon Levine, MariMed's Chief Executive Officer.

"In an industry environment where many operators continue to face pricing compression and limited growth, MariMed continues to strengthen profitability, expand branded distribution, and reinforce the market positioning of our core brands through disciplined operational execution," he continued.

"Our products maintained or grew their market-leading positions in the most popular categories across our wholesale markets, demonstrating our operational excellence across innovation, manufacturing, and sell-through. Following the recent historic rescheduling announcement and continued progress of our 2026 growth drivers, MariMed is well-positioned to capitalize on this transformative period for our industry."

"We also remain focused on disciplined capital execution, operational efficiency, and strengthening liquidity while continuing to invest in high-return growth opportunities that support long-term shareholder value creation."

Conference Call

MariMed management will host a conference call on

Thursday, May 14, 2026 at 8:00 a.m. Eastern time, to discuss these results. The conference call may be accessed through MariMed’s Investor Relations website, or by clicking the following lin k:

Q126 MRMD Earnings Call.

First Quarter 2026 Operational Highlight

During the first quarter, the Company announced the following development in the implementation of its strategic growth plan:

• March 2

: Announced a Restructuring and Exchange Agreement with the holders of the $14.725 million Series B Convertible Preferred Stock. The Agreement eliminated the Company's February 26, 2026 mandatory conversion date obligation and replaced it with a combination of long-dated instruments. The transaction extends the weighted average maturity of the obligation to 4.6 years, eliminating near-term refinancing risk and enhancing the Company's liquidity profile.

Discussion of Non-GAAP Financial Measures

MariMed’s management uses several different financial measures, both GAAP and non-GAAP, in analyzing and assessing the overall performance of its business, making operating decisions, and planning and forecasting future periods. The Company has provided in this release several non-GAAP financial measures: Non-GAAP Adjusted EBITDA and non-GAAP Adjusted EBITDA margin, Non-GAAP Gross margin, Non-GAAP Operating expenses and Non-GAAP Net income (loss), as supplements to Revenue, Gross margin, Operating expenses, Income (loss) from operations, Net income (loss) and other financial measures prepared in accordance with GAAP.

Management believes these non-GAAP financial measures are useful in reviewing and assessing the performance of the Company, and when planning and forecasting future periods, as they provide meaningful operating results by excluding the effects of expenses that are not reflective of its operating business performance. In addition, the Company’s management uses these non-GAAP financial measures to understand and compare operating results across accounting periods and for financial and operational decision-making. The presentation of these non-GAAP measures is not intended to be considered in isolation or as a substitute for the financial information prepared in accordance with GAAP.

Management believes that investors and analysts benefit from considering non-GAAP financial measures in assessing the Company’s financial results and its ongoing business, as it allows for meaningful comparisons and analysis of trends in the business. In particular, non-GAAP adjusted EBITDA is used by many investors and analysts themselves, along with other metrics, to compare financial results across accounting periods and to those of peer companies.

As there are no standardized methods of calculating non-GAAP financial measures, the Company’s calculations may differ from those used by analysts, investors and other companies, even those within the cannabis industry, and therefore may not be directly comparable to similarly titled measures used by others.

Management defines non-GAAP Adjusted EBITDA as income (loss) from operations, determined in accordance with GAAP, excluding the following items:

• depreciation and amortization of property and equipment;

• amortization of acquired intangible assets;

• impairment or write-downs of acquired intangible assets;

• inventory revaluation;

• stock-based compensation;

• severance;

• legal settlements; and

• acquisition-related and other expenses.

For further information, please refer to the publicly available financial filings available on MariMed's Investor Relations website, as filed with the U.S. Securities and Exchange Commission, or as filed with the Canadian securities regulatory authorities on the SEDAR website.

About MariMed... (truncated)io of cannabis brands, including

Betty's Eddies

™,

Bubby’s Baked

™,

Vibations

™,

InHouse

™, and

Nature’s Heritage

™, sets us apart as an industry leader. These trusted brands, crafted with quality and innovation, are recognized and loved by consumers across the country. With a commitment to excellence, MariMed continues to drive growth and set new standards in the cannabis industry. For additional information, visit www.marimedinc.com.

Financial statements

Income Statement

Three months ended March 31, — The following table summarizes the Company's consolidated financial highlights (in millions, except percentage amounts):

Three months ended March 31, – 2026 – (unaudited)Three months ended March 31, – 2025 – (unaudited)
Revenue39.537.9
GAAP Gross margin3940
Non-GAAP Gross margin4041
GAAP Net loss-3.8-5.5
Non-GAAP Net loss-3.2-3.9
Non-GAAP Adjusted EBITDA3.62.5
Non-GAAP Adjusted EBITDA margin97

Income Statement

Three months ended — (unaudited)

Three months ended – March 31, – 2026Three months ended – March 31, – 2025
Revenue39,48137,906
Cost of revenue24,20522,817
Gross profit15,27615,089
Gross margin38.739.8
Operating expenses:Personnel7,2547,341
Operating expenses:Marketing and promotion765908
Operating expenses:General and administrative6,8876,250
Operating expenses:Acquisition-related and other169112
Operating expenses:Bad debt761,388
Operating expenses:Total operating expenses15,15115,999
Operating expenses:Income (loss) from operations125-910
Interest and other (expense) income:Interest expense-1,976-1,762
Interest and other (expense) income:Interest income3624
Interest and other (expense) income:Gain on extinguishment of debt699
Interest and other (expense) income:Total interest and other expense, net-1,241-1,738
Interest and other (expense) income:Loss before income taxes-1,116-2,648
Interest and other (expense) income:Provision for income taxes2,6512,831
Interest and other (expense) income:Net loss-3,767-5,479
Interest and other (expense) income:Less: Net income attributable to noncontrolling interests1832
Interest and other (expense) income:Net loss attributable to common stockholders-3,785-5,511
Net loss per share attributable to common stockholders:Basic-0.01-0.01
Net loss per share attributable to common stockholders:Diluted-0.01-0.01
Weighted average common shares outstanding:Basic397,450382,557
Weighted average common shares outstanding:Diluted397,450382,557

Income Statement

Three months ended — (unaudited)

Three months ended – March 31, – 2026Three months ended – March 31, – 2025
Non-GAAP Adjusted EBITDAGAAP Income (loss) from operations125-910
Non-GAAP Adjusted EBITDADepreciation and amortization of property and equipment2,1531,807
Non-GAAP Adjusted EBITDAAmortization of acquired intangible assets810949
Non-GAAP Adjusted EBITDAStock-based compensation325547
Non-GAAP Adjusted EBITDAAcquisition-related and other169112
Non-GAAP Adjusted EBITDAAdjusted EBITDA3,5822,505
Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)GAAP Income from operations0.3-2.4
Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)Depreciation and amortization of property and equipment5.54.8
Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)Amortization of acquired intangible assets2.12.5
Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)Stock-based compensation0.81.4
Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)Acquisition-related and other0.40.3
Non-GAAP Adjusted EBITDA Margin (Non-GAAP adjusted EBITDA as a percentage of revenue)Adjusted EBITDA margin9.16.6

Income Statement

Three months ended — (unaudited)

Three months ended – March 31, – 2026Three months ended – March 31, – 2025
Product sales - retail21,72720,730
Product sales - wholesale17,51716,786
Other revenue237390
Total revenue39,48137,906

Balance Sheet

(unaudited)

March 31, 2026December 31, 2025
Current assets:Cash, cash equivalents and restricted cash7,9378,884
Current assets:Accounts receivable, net9,4399,114
Current assets:Inventory39,29636,601
Current assets:Notes receivable, current portion866866
Current assets:Other current assets3,2503,825
Current assets:Total current assets60,78859,290
Current assets:Property and equipment, net88,05489,385
Current assets:Intangible assets, net16,40017,210
Current assets:Goodwill24,00224,002
Current assets:Operating lease right-of-use assets7,5397,723
Current assets:Finance lease right-of-use assets3,4524,024
Current assets:Other assets950931
Current assets:Total assets201,185202,565
Current liabilities:Mortgages and notes payable, current portion3,2952,553
Current liabilities:Accounts payable15,10914,586
Current liabilities:Accrued expenses and other10,3579,509
Current liabilities:Deferred revenue1,4731,394
Current liabilities:Income taxes payable29,58926,981
Current liabilities:Operating lease liabilities, current portion1,9981,952
Current liabilities:Finance lease liabilities, current portion1,9382,092
Current liabilities:Total current liabilities63,75959,067
Current liabilities:Mortgages and notes payable, net of current portion76,02770,192
Current liabilities:Operating lease liabilities, net of current portion6,3876,616
Current liabilities:Finance lease liabilities, net of current portion1,5661,956
Current liabilities:Total liabilities147,739137,831
Mezzanine equitySeries B convertible preferred stock14,725
Mezzanine equityNew Series B convertible preferred stock6,933
Mezzanine equityTotal mezzanine equity6,93314,725
Stockholders’ equityCommon stock399397
Stockholders’ equityAdditional paid-in capital179,723179,405

Cash Flow

Three months ended — (unaudited)

Three months ended – March 31, – 2026Three months ended – March 31, – 2025
Cash flows from operating activities:Net loss attributable to common stockholders-3,785-5,511
Cash flows from operating activities:Net income attributable to noncontrolling interests1832
Adjustments to reconcile net loss to cash provided by operating activities:Depreciation and amortization of property and equipment2,1531,807
Adjustments to reconcile net loss to cash provided by operating activities:Amortization of intangible assets810949
Adjustments to reconcile net loss to cash provided by operating activities:Stock-based compensation325547
Adjustments to reconcile net loss to cash provided by operating activities:Amortization of debt discount115105
Adjustments to reconcile net loss to cash provided by operating activities:Amortization of debt issuance costs1818
Adjustments to reconcile net loss to cash provided by operating activities:Payment-in-kind interest30
Adjustments to reconcile net loss to cash provided by operating activities:Bad debt expense761,388
Adjustments to reconcile net loss to cash provided by operating activities:Obligations settled with common stock1
Adjustments to reconcile net loss to cash provided by operating activities:Loss on disposal of assets111
Adjustments to reconcile net loss to cash provided by operating activities:Gain on extinguishment of debt-699
Changes in operating assets and liabilities:Accounts receivable, net-401-303
Changes in operating assets and liabilities:Deferred rents receivable12
Changes in operating assets and liabilities:Inventory-2,695-453
Changes in operating assets and liabilities:Other current assets999240
Changes in operating assets and liabilities:Other assets-19-2,542
Changes in operating assets and liabilities:Accounts payable52386
Changes in operating assets and liabilities:Accrued expenses and other8291,888
Changes in operating assets and liabilities:Deferred revenue7459
Changes in operating assets and liabilities:Income taxes payable2,6082,829
Changes in operating assets and liabilities:Net cash provided by operating activities9491,293
Cash flows from investing activities:Purchases of property and equipment-373-266
Cash flows from investing activities:Business combinations, net of cash acquired, and asset purchases231
Cash flows from investing activities:Advances toward future business combinations and asset purchases-50
Cash flows from investing activities:Purchases and renewals of cannabis licenses-380-56
Cash flows from investing activities:Proceeds from notes receivable26
Cash flows from investing activities:Net cash used in investing activities-753-115

Cash Flow

Three months ended — (unaudited)

Three months ended – March 31, – 2026Three months ended – March 31, – 2025
Cash flows from financing activities:Principal payments of mortgages-414-401
Cash flows from financing activities:Principal payments of promissory notes-236-478
Cash flows from financing activities:Principal payments of finance leases-444-322
Cash flows from financing activities:Distributions-49-58
Cash flows from financing activities:Net cash used in financing activities-1,143-1,259
Cash flows from financing activities:Net decrease in cash and cash equivalents-947-81
Cash flows from financing activities:Cash and equivalents, beginning of year8,8847,201
Cash flows from financing activities:Cash and cash equivalents, end of period7,9377,120
Full release

Important Caution Regarding Forward-Looking Statements

The information in this release contains “forward-looking” statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, which are subject to several risks and uncertainties.

All statements other than statements of historical facts contained in this release, including without limitation statements regarding projected financial results for 2026, including anticipated openings of dispensaries and facilities, timing of regulatory approvals, plans and objectives of management for future operations, are forward-looking statements.

Without limiting the foregoing, the words “anticipates”, “believes”, “estimates”, “expects”, “expectations”, “intends”, “may”, “plans”, and other similar language, whether in the negative or affirmative, are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.

Forward-looking statements are based on our current beliefs and assumptions regarding our business, timing of regulatory approvals, the ability to obtain new licenses, business prospects and strategic growth plan, and other future conditions.

Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict.

Our actual results may differ materially from those contemplated in these forward-looking statements due to various risks, uncertainties, and other important factors, including, among others, reductions in customer spending, our ability to recruit and retain key personnel, and disruptions from the integration efforts of acquired companies.

These factors are not intended to be an all-encompassing list of risks and uncertainties that may affect our business and results of operations.

These statements are not a guarantee of future performance and involve risk and uncertainties that are difficult to predict, including, among other factors, changes in demand for the Company’s services and products, changes in the law and its enforcement, and changes in the economic environment.

Additional information regarding these and other factors can be found in our reports filed with the U.S. Securities and Exchange Commission.

In providing these forward-looking statements, the Company expressly disclaims any obligation to update these statements publicly or otherwise, whether as a result of new information, future events or otherwise, except as required by law.

All trademarks and service marks are the property of their respective owners.

Neither the CSE nor its Regulation Services accepts responsibility for the adequacy or accuracy of this release.

For More Information Contact:

Howard Schacter, Chief Communications Officer

Email: hschacter@marimedinc.com

Phone: (781) 277-0007

# # #

MariMed Inc.

Condensed Consolidated Balance Sheets

(in thousands)

(unaudited)

MariMed Inc.

Condensed Consolidated Statements of Operations

(in thousands, except percentages and per share amounts)

(unaudited)

MariMed Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(unaudited)

MariMed Inc.

Reconciliation of Non-GAAP and GAAP Financial Measures

(in thousands, except percentages)

(unaudited)

MariMed Inc.

Supplemental Information

Revenue Components

(in thousands)

(unaudited)

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Marimed earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.